Abcellera Biologics is trading 5.4% down today at $6.90 as investors lock in profits following a sharp run-up in share price.
- The stock recently gained more than 40% driven by optimism surrounding Q1 2026 earnings and upcoming clinical pipeline catalysts.
- With no fresh company-specific news or sector shocks reported on July 10, 2026, the decline appears to be a result of continued volatility and profit-taking.
- Analysts and social media traders had previously highlighted the rapid appreciation, suggesting a technical pullback after the significant post-earnings rally.